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Abstract
Background: It is speculated that high saturated fat very low carbohydrate diets (VLCARB) have
adverse effects on cardiovascular risk but evidence for this in controlled studies is lacking. The
objective of this study was to compare, under isocaloric conditions, the effects of a VLCARB to 2
low saturated fat high carbohydrate diets on body composition and cardiovascular risk.
Methods: Eighty three subjects, 48 ± 8 y, total cholesterol 5.9 ± 1.0 mmol/L, BMI 33 ± 3 kg/m2
were randomly allocated to one of 3 isocaloric weight loss diets (6 MJ) for 8 weeks and on the same
diets in energy balance for 4 weeks: Very Low Fat (VLF) (CHO:Fat:Protein; %SF = 70:10:20; 3%),
High Unsaturated Fat (HUF) = (50:30:20; 6%), VLCARB (4:61:35; 20%)
Results: Percent fat mass loss was not different between diets VLCARB -4.5 ± 0.5, VLF-4.0 ± 0.5,
HUF -4.4 ± 0.6 kg). Lean mass loss was 32-31% on VLCARB and VLF compared to HUF (21%) (P
< 0.05). LDL-C increased significantly only on VLCARB by 7% (p < 0.001 compared with the other
diets) but apoB was unchanged on this diet and HDL-C increased relative to the other 2 diets.
Triacylglycerol was lowered by 0.73 ± 0.12 mmol/L on VLCARB compared to -0.15 ± 0.07 mmol/
L on HUF and -0.06 ± 0.13 mmol/L on VLF (P < 0.001). Plasma homocysteine increased 6.6% only
on VLCARB (P = 0.026). VLCARB lowered fasting insulin 33% compared to a 19% fall on HUF and
no change on VLF (P < 0.001). The VLCARB meal also provoked significantly lower post prandial
glucose and insulin responses than the VLF and HUF meals. All diets decreased fasting glucose,
blood pressure and CRP (P < 0.05).
Conclusion: Isocaloric VLCARB results in similar fat loss than diets low in saturated fat, but are
more effective in improving triacylglycerols, HDL-C, fasting and post prandial glucose and insulin
concentrations. VLCARB may be useful in the short-term management of subjects with insulin
resistance and hypertriacylglycerolemia.
Published: 11 January 2006
Nutrition & Metabolism 2006, 3:7 doi:10.1186/1743-7075-3-7
Received: 21 September 2005
Accepted: 11 January 2006
This article is available from: http://www.nutritionandmetabolism.com/content/3/1/7
© 2006 Noakes et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
Page 2 of 13
(page number not for citation purposes)
Background
Obesity, particularly abdominal obesity, contributes sub-
stantially and directly to cardiovascular risk as well as
exacerbating associated risk factors such as dyslipidaemia,
hypertension and diabetes [1,2]. Although weight loss has
been shown to reverse many of these associated risk fac-
tors[3] defining optimum long-term eating patterns for
weight loss is important in order to optimize risk factor
reduction, given that the evidence for the benefit on cardi-
ovascular mortality of weight reduction alone is conflict-
ing [4,5]. The resurgence of interest in diets promoting
low carbohydrate intake or high protein intake is occur-
ring at a time where there is mounting evidence that high
intakes of refined carbohydrates have paralleled the devel-
opment of obesity and type 2 diabetes [6]). There have
been a number of studies examining the effect of very low
carbohydrate diets using an ad libitum approach as per
the Atkins diet and they have demonstrated superior
weight loss on very low carbohydrate diets compared to
low fat high carbohydrate diets over a 6 month period [7-
13]. Although this seems to be consistent with the notion
that very low carbohydrate diets have a metabolic advan-
tage[11,14], the design of these studies was not planned
to test this hypothesis as they assessed very low carbohy-
drate diets on an ad libitum basis (thereby not controlled
for kilojoule intake) and assessed cardiovascular risk fac-
tors during energy restriction which may exaggerate the
net effects of weight loss on that diet composition.
The aim of this study was therefore to evaluate under iso-
caloric conditions a very low carbohydrate dietary pattern
(<20 g carbohydrate/day) compared to a very low fat diet
or a low saturated fat high unsaturated fat dietary pattern.
Endpoints were body composition and a range of conven-
tional and novel cardiovascular risk markers.
Methods
Subjects and design
Ninety subjects with at least one cardiovascular risk factor
in addition to a BMI>28 were recruited by public adver-
tisement to participate in a clinical trial of 12 weeks dura-
tion. Seven subjects withdrew before randomization and
a further 16 withdrew during the study leaving a total of
sixty seven subjects that completed the study (Figure 1).
Subjects were matched on the basis of age, gender, BMI
and randomly allocated to one of 3 dietary intervention
groups (Table 1). There was an intensive weight loss
period of 8 weeks and a weight maintenance period of 4
weeks duration. The protocol and potential risks and ben-
efits of the study were fully explained to each subject
before they provided written informed consent. A sche-
matic representation of study design is shown in Figure 2.
All experimental procedures were approved by the
Human Ethics Committees of the Commonwealth Scien-
tific Industrial Research Organisation (CSIRO).
Dietary intervention
The diets were designed to be isocaloric and 30% energy
restricted (~6000 kJ) for 8 weeks, followed by 4 weeks on
the same macronutrient proportions but maintaining
energy balance. Energy requirements of individuals were
calculated and 30% energy restriction calculated accord-
ingly The planned macronutrient profiles of the treatment
diets were as follows: Very Low Fat (VLF) (CHO:Fat:Pro-
tein; %SF = 70:10:20; 3%), High Unsaturated Fat (HUF) =
(50:30:20; 6%), VLCARB (4:61:35; 20%). Templates for
the dietary patterns were developed for 5.5 MJ, 6 MJ, 7 MJ
Schematic representation of randomization Figure 1
Schematic representation of randomization.
Schematic representation of study design Figure 2
Schematic representation of study design. U = 24 hour 
urine. MTT = meal tolerance test. GTT = glucose tolerance 
test. DXA = Dual Xray Absorptiometry. ↑ = blood sample. 
VLCARB = very low carbohydrate diet (n = 24) VLF = very 
low fat diet (n = 22) HUF = high unsaturated fat (n = 21).Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
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and 8 MJ and these served as a basis for minor individual
adjustments.
Key foods for each diet (2200 kilojoules or 36% of total
energy) representative of the diets' macronutrient profile
were supplied every 2 weeks for the 12 wk study. Foods
provided were uncooked but pre-weighed to facilitate
compliance. The dietary pattern was structured to include
specific daily quantities of foods to ensure the correct
macronutrient and energy requirements (Table 2A). These
foods were listed in a checklist which subjects completed
on a daily basis. Detailed dietary instruction, meal plan-
ning and recipe information was provided at baseline and
every 2 weeks by a qualified dietitian. Checklists of pre-
scribed foods and additional foods were checked, and 3 d
weighed food records were collected every 2 wks to assess
dietary compliance up to the 12 wk time point. At week 8,
adjustment of energy intake was titrated upwards to
restore the daily energy deficit based on the calculated
daily deficit assessed from the previous 4 wks weight loss.
Standard meal plans for each diet were developed for a
range of energy levels in 1000 kJ increments which served
as the basis for the revised energy balance prescription.
Subjects were counselled by a dietitian on the dietary pro-
tocol and on how to keep dietary-intake checklists for all
foods consumed each day over the study duration. The
subjects' body weight and dietary-intake checklist were
monitored every 2 weeks and dietary adjustments were
made if necessary. Three consecutive days (one weekend
and 2 weekdays) of the checklists from each 2-week
period were analyzed by "Diet/1 Nutrient Calculation"
software (Xyris Software 1998, Highgate Hill, Australia), a
computerized database of Australian foods. Recipes were
entered as proportions of the original ingredients. The
database had been extensively modified by our group to
add new foods and recipes. A questionnaire with numeri-
cal rating scale was used to assess diet acceptability on a
range of parameters including palatability, ease of adher-
ence, effect on hunger, fullness, nausea and desire to eat,
and cravings.
Clinical and biochemical analyses
Blood samples were taken according to the schedule as per
Figure 2. Venous blood samples were taken in the morn-
ing after an overnight fast for determination of plasma
glucose, insulin, ketones and lipid concentrations. Fasting
Table 1: Subject characteristics at baseline1
VLCARB VLF HUF
males/females 4/20 5/17 3/18
BMI kg/m2 32.5 ± 3.1 32.6 ± 4.0 33.4 ± 3.6
AGE y 48.4 ± 8.0 50.7 ± 10.3 46.1 ± 9.5
Total Cholesterol mmol/L 5.8 ± 1.0 5.6 ± 1.1 6.0 ± 1.1
LDL-C mmol/L 3.8 ± 0.8 3.6 ± 1.1 4.0 ± 1.1
HDL-C mmol/L 1.2 ± 0.2 1.3 ± 0.3 1.2 ± 0.2
Triacylglycerols mmol/L 1.8 ± 0.9 1.5 ± 0.6 1.6 ± 0.5
1 Data are Mean ± SD. VLCARB = very low carbohydrate diet (n = 24) VLF = very low fat diet (n = 22) HUF = high unsaturated fat (n = 21)
Table 2A: Food profile of treatment diets
VLCARB VLF HUF
Cheese, full fat 70 g High fibre cereal 40 g High fibre cereal 32 g
Milk, full fat 125 g Bread, wholegrain 105 g Bread, wholegrain 70 g
Lean meat, chicken 350 g Low fat biscuits 60 g Milk, skim 300 g
Eggs 2 Milk, skim 250 g Cheese full fat 20 g 2/week
Very low carbohydrate vegetables 2 cups Cheese low fat 20 g Yoghurt, skim 200 g × 3/week
Almonds 50 g Rice or pasta, dry 50 g Pasta or rice, dry 100 g × 4/week
Butter 20 g Fresh fruit 300 g Nuts, mixed 20 g
Dried fruit 50 g Salad vegetables 100 g
Lean meat, chicken 100 g Fresh fruit 300 g
Salad vegetables 100 g Pulses, cooked 100 g × 2/week
Low carbohydrate vegetables 2 cups Lean meat, chicken, 150 g 5/week
Fish 150 g/week
Sardines 3 whole/week
Tuna 50 g × 2/week
Low carbohydrate vegetables 1.5 cups
Potato 1 × 3/week
Unsaturated oil or margarine 25 gNutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
Page 4 of 13
(page number not for citation purposes)
serum was collected, and stored at -20°C until the end of
the study. All lipid assays were performed in a single run
at the end of the 12-week study on a Roche Cobas-Bio cen-
trifugal Analyser using standard Roche enzymatic kits.
HDL cholesterol was measured after PEG 6000 precipita-
tion of apoB containing lipoproteins. Fasting lipids were
taken on two consecutive days and then values averaged
at each of the timepoints. Coefficients of variance (CV) for
all assays were less than 5% with the exception of insulin
for which the CV was 9.75%. Total apoB (B100 and B48)
was measured by immunoturbidimetry using Roche antis-
era. Apo B48 levels were determined directly in serum
using a Western Blotting procedure as previously
described by James et al [15]. Following visualisation
using enhanced chemiluminescence (Amersham, Little
Chalfont, UK) apo B48 bands were identified and quanti-
fied by densitometry against purified apo B48 protein of
known mass using NIH Image (version 1.6.3). The mean
intra- and inter-assay CV for apo B48 were each less than
4% Plasma levels of ketones were assayed using an enzy-
matic method using the principle that β hydroxybutyrate
in the presence of NAD is converted to acetoacetate and
NADH by β-hydroxybutyrate dehydrogenase. The NADH
produced was quantified spectrophotometrically on a
Cobas-Bio centrifugal Analyser measured by absorbance
at 340 nm.
At weeks 0 and 12, a single venous blood sample was
taken for the determination of homocysteine, folate and
B12 which were measured in a certified commercial labo-
ratory (Institute of Medical and Veterinary Science,
Adelaide, South Australia). Serum CRP concentrations
(CV 3.5%) were measured in duplicate at baseline and at
week 12 with an ultrasensitive ELISA (Alpha Diagnostica).
Serum insulin was measured by radioimmunoassay
(Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden)
while CRP was measured by immunoturbidimetry using
Roche antisera.
Table 2B: Foods and nutrient profiles provided in Meal Tolerance Test (MTT)
VLCARB Amount(g) Energy Protein (g) Fat (g) Carbohydrate (g)
Cheese 40 676 10 14 0
Corned beef 60 247 11 2 0
Ham 60 272 11 2 0
Egg 50 316 7 5 0
Whole milk 50 136 2 2 2
Almonds 20 486 4 11 1
Salad 50 26 1
total 2159 45 36 4
% energy 36% 61% 3%
VLF
Bread wholemeal 100 939 10 3 39
Cheese reduced fat 10 137 3 2 0
Corned beef 10 41 2 0 0
Ham 10 45 2 0 0
Skim milk 150 276 7 0 10
Fruit bar 1 bar 548 1 1 29
Sultanas 15 192 0 0 11
total 2178 25 7 89
% energy 20% 13% 67%
HUF
Bread wholemeal 110 1033 11 3 43
Margarine polyunsaturated 12 359 0 10 0
Corned beef 20 82 4 1 0
Salmon 20 146 4 2 0
Yoghurt 200 410 10 0 12
Baked beans 40 114 2 0 4
Salad 50 26 0 0 1
total 2169 32 16 60
% energy 26% 28% 46%
VLCARB = very low carbohydrate diet (n = 24) VLF = very low fat diet (n = 22) HUF = high unsaturated fat (n = 21)Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
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A 24-hour urine sample was collected for the assessment
of the urea/creatinine ratio, calcium, sodium and potas-
sium excretion, as well as deoxy-pyridinoline/creatinine
and pyridinoline/creatinine ratios (biomarkers of bone
turnover) were also assessed from the 24-hour urine sam-
ple at weeks 0 and 12. Urine samples were frozen, and
urea and creatinine was measured in one run at the end of
the study using a Hitachi auto analyzer (Roche, Indianap-
olis, USA). Urinary pyridinium crosslinks (markers of
bone turnover) were measured using HPLC. Urine sam-
ples were measured at the Institute of Medical and Veteri-
nary Science, Adelaide, South Australia) for calcium,
phosphate and sodium using proprietary techniques on
the Olympus AU5400 chemistry analyzer (Japan).
Also at weeks 0 and 12, measurements of body composi-
tion and a 75 g oral glucose tolerance test (GTT) and on a
subsequent day a 3-hour meal tolerance test (MTT) using
meals that were representative of the diet to which the
subjects were assigned (Table 2B), were performed.
Venous blood samples for the determination of glucose,
insulin, free fatty acid concentrations were taken prior to
consuming the test meals as well as at 30, 60, 120 and 180
minutes after the meal.
The homeostatic model assessment (HOMA) was used as
a surrogate measure of insulin sensitivity and was calcu-
lated as [fasting serum insulin (mU/L) × fasting plasma
glucose (mmol/L)/22.5] ([16]). Total glucose, insulin and
area under the curve during the 3-hour GTT and MTT was
calculated geometrically using the trapezoidal rule [17].
Body composition was determined by whole body DEXA
using a Norland Densitometer XR36; (Norland Medical
Systems, Fort Atkinson, Wisconsin, USA; CV of 2.3 ± 0.7%
for total body fat mass and 2.1 ± 0.4% for lean mass) at
baseline (prior to commencement) and at 12 weeks.
Blood pressure was measured using an HDI/Pulsewave™
instrument (Hypertension Diagnostics inc. Minnesota,
USA).
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows 10.0 software (SPSS Inc, Chicago, USA). Baseline
measurements were assessed using two-factor ANOVA
with diet and gender as the fixed factors. The effect of the
diet intervention was assessed using repeated-measures
ANOVA; for each dependent variable, the measurements
at weeks 0, 4, 8, and 12 are the within-subject factor (i.e.
time) and diet and gender are the between-subject factors.
Week 0 and 12 response curves following the GTT and test
meals were compared using repeated measures ANOVA
with week and blood sampling time (or AUC) as the
within-subject factors and diet as the between-subject fac-
tors. When significant time-by-diet effects were found,
post hoc sub-group analysis was performed using Tukey's
test. The study had 80% power (α = 0.05) to detect differ-
ences between dietary groups of 3.6 kg in body weight, 0.9
kg in lean and fat mass, 3 mU/L in fasting insulin and 0.2
mmol/L in LDL-cholesterol. Significance was set at P <
0.05. All data except baseline characteristics are presented
as means ± SEM, unless stated otherwise.
Results
Dietary compliance
Reported dietary intake was consistent with the prescribed
dietary treatments (Table 3). Compliance to dietary treat-
ment was also confirmed by a change in plasma ketones
Table 3: Nutrient intake by dietary treatment during weight loss and weight maintenance assessed using weighed food records12
VLCARB VLF HUF
Nutrient Weight loss Maintenance Weight loss Maintenance Weight loss Maintenance
Energy (kJ) 6193 (± 82) 7706 (± 167) 6061 (± 168) 7000 (± 333) 5996 (± 88) 7659 (± 201)
% energy protein3 33.1 (± 0.85) 30.5 (± 0.91) 19.9 (± 0.33) 20.3 (± 0.55) 22.6 (± 0.46) 21.4 (± 0.51)
% energy fat3 55.1 (± 1.96) 54.3 (± 2.53) 11.7 (± 0.32) 12.5 (± 0.59) 27.4 (± 0.84) 28.0 (± 0.88)
% energy carbohydrate3 8.8 (± 2.71) 12.4 (± 3.38) 67.7 (± 0.60) 66.0 (± 0.92) 47.9 (± 0.83) 48.7 (± 1.07)
% energy saturated fat4 17.6 (± 0.77) 17.7 (± 1.01) 4.5 (± 0.16) 5.1 (± 0.30) 5.4 (± 0.18) 6.0 (± 0.32)
% energy MUFA3 27.0 (± 1.16) 26.2 (± 1.41) 3.3 (± 0.11) 3.6 (± 0.21) 12.0 (± 0.48) 12.3 (± 0.51)
% energy PUFA3 6.3 (± 0.13) 6.5 (± 0.28) 1.7 (± 0.03) 1.8 (± 0.16) 7.6 (± 0.29) 7.2 (± 0.30)
Calcium (mg)5 959 ± 14 1297 ± 58 867 ± 32 1079 ± 55 969 ± 19 1169 ± 43
1 mean ± SEM, VLCARB = very low carbohydrate (n = 24) VLF= very low fat (n = 22) HUF = high unsaturated fat (n = 21)
MUFA = monounsaturated fat, PUFA = polyunsaturated fat
2 Three days (2 week days and 1 weekend day) of dietary data were analysed at weeks 2, 4, 6 and 8 during the weight loss period and at weeks 10 
and 12 during the maintenance period. No significant differences were found between the four diet records in the weight loss period or between 
the two records for the maintenance period, so data for recordings in each period were averaged.
3 Significant main effect of diet using one way ANOVA with all diets significantly different from each other (P < 0.01)
4 Significant main effect of diet using one way ANOVA; VLF vs HUF (p = 0.126) and VLCARB different to VLF and HUF (P < 0.01)
5 Significant main effect of diet using one way ANOVA; VLF different to VLCARB and HUF (P < 0.05)Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
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between diets. VLCARB produced higher plasma levels of
ketones (β hydroxybutyrate and acetoacetate) than the
VLF or HUF diet treatments (P < 0.01), indicating adher-
ence to a very low carbohydrate intake during the study
(Figure 3). Despite continued apparent compliance to the
diet plasma ketones declined with time.
Weight loss
Each treatment group reduced weight over the 8 wk
energy restriction period and maintained this weight dur-
ing the subsequent 4 wk period (Figure 4). There were no
significant differences in absolute weight loss by diet com-
position, with a net weight loss of 8.0 ± 0.6 kg (n = 24),
6.7 ± 0.7 kg (n = 22) and 6.4 ± 0.6 kg (n = 21) on the
VLCARB, VLF and HUF diets respectively (P = 0.18). How-
ever, percentage change in weight from baseline differed
significantly by diet (P = 0.034) with the VLCARB diet
resulting in a greater weight loss of 9.2% compared to the
VLF (7.3%) and HUF (7.0%). After applying Tukey's post
hoc test however, only HUF remained significantly differ-
ent to VLCARB (P = 0.044).
Body composition
DEXA data indicated both the VLCARB and VLF diets
resulted in significantly more lean mass loss as a propor-
tion of weight loss (32% and 31%) compared to the HUF
diet (21%) (P < 0.05) whereas the proportion of fat loss
did not differ between diets (Table 4). DEXA data also
indicated no significant differences in regional fat or lean
mass loss between diets.
Cardiovascular risk markers
There was a significant main effect of diet on LDL-C with
a net increase of 0.18 ± 0.18 mmol/L on the VLCARB diet,
but net decreases of 0.40 ± 0.11 mmol/L on the VLF and
0.34 ± 0.14 mmol/L on HUF (p = 0.008 unadjusted and p
= 0.006 adjusted for weight loss) (Table 5). However, the
effect of diet composition on apoB concentrations was
not significant (p = 0.418) although concentrations
declined with weight loss overall (p = 0.011). ApoB was
unchanged in the VLCARB group. Diet significantly
affected apoB48 (p = 0.05) but not after adjusting for
weight loss (p = 0.11), increasing on VLF and decreasing
on VLCARB and HUF (data not shown).
Diet composition significantly affected the change in
HDL-C with or without correcting for weight loss (p =
0.023 unadjusted and p = 0.029 adjusted for weight loss)
with an increase on VLCARB (0.06 ± 0.03 mmol/L)
Plasma ketones during weight loss and weight maintenance,  according to dietary treatment1 Figure 3
Plasma ketones during weight loss and weight main-
tenance, according to dietary treatment1. 1mean ± 
SEM. * denotes a significant difference of VLCARB from VLF 
and HUF (p < 0.05) by one way ANOVA at each time point 
for main effect of diet (p < 0.05) and post hoc Tukeys test to 
detect differences (p < 0.05). VLCARB = very low carbohy-
drate diet (n = 24) VLF = very low fat diet (n = 22) HUF = 
high unsaturated fat (n = 21)
Table 4: Body composition changes according to dietary treatment1
DIET VLCARB VLF HUF
Lean mass at baseline (kg) 46.5 ± 1.9 48.5 ± 2.6 46.4 ± 2.2
Lean mass after weight loss (kg) 43.9 ± 1.8 46.5 ± 2.3 45.0 ± 2.0
% change2 -2.6 ± 0.4a -2.1 ± 0.4a -1.4 ± 0.4b
Fat mass at baseline (kg) 37.6 ± 1.3 37.9 ± 2.2 40.7 ± 1.6
Fat mass after weight loss (kg) 33.1 ± 1.3 33.9 ± 2.2 36.3 ± 1.4
% change in fat mass -4.5 ± 0.5a -4.0 ± 0.5a -4.4 ± 0.6a
% change in weight3 -8.0 ± 0.6a -6.7 ± 0.7a -6.4 ± 0.6b
1 mean ± SEM
VLCARB = very low carbohydrate (n = 24) VLF = very low fat (n = 22) HUF = high unsaturated fat (n = 21)
2 Significant effect of diet by one way ANOVA and screening weight as a covariate (P = 0.022).
3 Significant effect of diet by one way ANOVA and screening weight as a covariate (P = 0.034).
Variables with different superscripts are significantly different by one way ANOVA with Tukey's test for post hoc analysis p < 0.05.Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
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whereas the other diets resulted in similar net decreases of
0.06 ± 0.03 mmol/L.
Similarly diet had a significant lowering effect on TG (p =
0.001 unadjusted and p = 0.002 adjusted for weight loss)
with VLCARB having the greatest TG reduction (-0.73 ±
0.12 mmol/L) followed by the HUF diet (-0.15 ± 0.07
mmol/L) and VLF the least change (-0.06 ± 0.13 mmol/L).
Inflammatory markers
Five subjects had C reactive protein (CRP) >15 mg/L at
baseline or at the completion of the study and were
excluded from the analysis. All diets resulted in a signifi-
cant decrease in CRP with weight loss, independently of
diet (p = 0.037).
Plasma folate, homocysteine and B12
The main effect of weight loss or diet composition on
changes in plasma folate failed to reach statistical signifi-
cance (p = 0.106 and p = 0.09 respectively) whereas
plasma homocysteine increased 6.6% on VLCARB,
decreased 6.8% on the VLF and remained unchanged on
the HUF diet (P = 0.026 for diet effect) (Table 5). Increases
in homocysteine concentrations were observed in 16/24
subjects on VLC, 10/22 on VLF and 10/21 on HUF. There
were no changes in plasma B12 levels over the course of
the study and levels remained static at 266 ± 13 pmol/L.
Blood pressure
There was no significant effect of diet composition on
blood pressure changes with weight loss resulting in a net
Table 5: Plasma lipoproteins, glucose, insulin, folate and homocysteine concentrations during the dietary interventions1
Baseline Week 4 Week 8 Week 12 Change3
Total Cholesterol mmol/L VLCARB 5.92 ± 0.21 5.38 ± 0.20 5.68 ± 0.29 5.82 ± 0.26 -0.09 ± 0.20
VLF 5.64 ± 0.23 4.83 ± 0.20 4.94 ± 0.23 5.15 ± 0.26 -0.49 ± 0.14
HUF 6.09 ± 0.23 5.11 ± 0.23 5.27 ± 0.26 5.62 ± 0.24 -0.47 ± 0.15
LDL Cholesterol2 mmol/L VLCARB 3.83 ± 0.18 3.57 ± 0.21 3.89 ± 0.28 4.01 ± 0.26 0.18 ± 0.18a
VLF 3.65 ± 0.22 3.05 ± 0.18 3.16 ± 0.20 3.25 ± 0.22 -0.40 ± 0.11b
HUF 4.12 ± 0.24 3.38 ± 0.20 3.54 ± 0.25 3.78 ± 0.22 -0.34 ± 0.14b
ApoB g/L VLCARB 1.01 ± 0.05 0.94 ± 0.05 1.00 ± 0.05 -0.02 ± 0.05
VLF 0.97 ± 0.05 0.85 ± 0.05 0.89 ± 0.06 -0.07 ± 0.02
HUF 1.05 ± 0.06 0.93 ± 0.06 0.99 ± 0.05 -0.06 ± 0.02
HDL Cholesterol2 mmol/L VLCARB 1.26 ± 0.05 1.27 ± 0.05 1.26 ± 0.05 1.32 ± 0.05 0.06 ± 0.03a
VLF 1.31 ± 0.07 1.18 ± 0.05 1.15 ± 0.06 1.25 ± 0.06 -0.06 ± 0.04b
HUF 1.26 ± 0.05 1.15 ± 0.05 1.15 ± 0.05 1.19 ± 0.04 -0.06 ± 0.03b
Triacylglycerols2 mmol/L VLCARB 1.83 ± 0.19 1.20 ± 0.12 1.16 ± 0.10 1.11 ± 0.10 -0.73 ± 0.12a
VLF 1.51 ± 0.13 1.31 ± 0.10 1.38 ± 0.12 1.44 ± 0.13 -0.06 ± 0.13b
HUF 1.56 ± 0.11 1.27 ± 0.12 1.29 ± 0.11 1.42 ± 0.12 -0.15 ± 0.07b
Glucose mmol/L VLCARB 5.3 ± 0.1 5.2 ± 0.1 5.3 ± 0.1 5.3 ± 0.1 -0.1 ± 0.1
VLF 5.3 ± 0.1 5.1 ± 0.1 5.2 ± 0.1 5.3 ± 0.1 -0.1 ± 0.1
HUF 5.4 ± 0.1 5.4 ± 0.1 5.2 ± 0.1 5.2 ± 0.1 -0.2 ± 0.1
Insulin2 mU/L VLCARB 10.7 ± 1.1 8.2 ± 0.8 8.1 ± 1.0 7.1 ± 0.8 -3.6 ± 0.5a
VLF 8.6 ± 0.7 8.2 ± 0.7 7.8 ± 0.8 9.9 ± 1.9 1.3 ± 1.7b,c
HUF 9.1 ± 0.6 9.0 ± 0.6 7.9 ± 0.6 7.4 ± 0.7 -1.7 ± 0.5a,c
Folate nmol/L VLCARB 23.13 ± 1.46 22.52 ± 1.03 -0.61 ± 0.84
VLF 23.99 ± 1.42 27.54 ± 1.10 3.54 ± 1.30
HUF 23.95 ± 1.32 24.83 ± 1.61 0.88 ± 1.82
Homocysteine2 umol/L VLCARB 7.28 ± 0.33 7.76 ± 0.39 0.56 ± 0.27a
VLF 7.30 ± 0.45 6.80 ± 0.34 -0.50 ± 31b,c
HUF 7.14 ± 0.32 7.19 ± 0.30 -0.04 ± 0.22a,c
C reactive protein mg/L VLCARB 5.27 ± 0.71 . 4.51 ± 0.60 -0.76 ± 0.56
VLF 4.52 ± 0.78 3.42 ± 0.70 -1.10 ± 0.50
HUF 4.52 ± 0.70 4.17 ± 0.71 -0.35 ± 0.71
1mean ± SEM
VLCARB = very low carbohydrate (n = 24) VLF = very low fat (n = 22) HUF = high unsaturated fat (n = 21)
2 Significant main effect of diet using repeated measures ANOVA with time as the within subject factor and diet as the between subject factor after 
adjustment for weight loss as a covariate (P < 0.05)
3 When significant main effect of diet detected, post hoc analysis was conducted using Tukeys test. Variables with the different superscripts are 
significantly different from one another (P < 0.05)Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
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reduction in blood pressure of 7 ± 2 mmHg systolic and 3
± 1 mmHg diastolic blood pressure.
Glucose and insulin
Fasting glucose decreased with weight loss by 2% (p =
0.036) independently of diet composition (p = 0.10)
(Table 5). However, diet composition significantly
affected fasting insulin levels (main effect of diet p = 0.004
unadjusted and p = 0.006 adjusted for weight loss) with
the VLCARB diet lowering fasting insulin concentrations
by 33%, HUF by 19% whereas it increased 15% on VLF
(Table 5).
Post prandial glucose and insulin responses to oral glucose 
and test meals
At baseline, glucose tolerance (as assessed by the total area
under the curve) was not different according to diet allo-
cation (P = 0.552) but the insulin response to glucose was
significantly different (P = 0.038) with a greater insulin
AUC in the VLCARB group compared to the other two
groups (P < 0.05). There was a significant effect of diet on
the test meal glucose response (P = 0.016) (Figure 5) with
the VLCARB meal provoking a lower glucose response
than the VLF meal (P = 0.014 post hoc analysis) and the
HUF meal (P = 0.054 post hoc analysis). This effect was
strengthened if adjustment was made for the differences
in baseline insulin AUC as a covariate (P = 0.005). The
VLCARB meal also induced an insulin response that was
substantially lower compared to HUF and VLF meals
(both P < 0.001 on post hoc analysis). Weight loss on the
diets resulted in improvements in glucose tolerance in
subjects allocated the VLF and HUF diets (P < 0.05)
whereas no changes in glucose tolerance were observed in
the VLCARB group (Figure 6). However, the insulin
response to the glucose challenge was significantly low-
ered after weight loss on VLCARB (P = 0.016) but the
small reductions observed on VLF and HUF diets were not
statistically significant. Weight loss provoked a lower
insulin response to the test meals (P < 0.05).
Urinary bone markers and electrolytes
Calcium excretion increased 25% on the VLCARB diet yet
decreased 12–16% on both the VLF and HUF (Table 6).
Sodium excretion was not significantly different by time
or diet whereas potassium excretion increased only on
VLF (P < 0.001). Markers of bone turnover Dpr:Cr and
Pyr:Cr increased significantly overall by 15% with weight
loss (P < 0.001), but no specific diet composition effects
were observed.
Discussion
This study has attempted to evaluate isocaloric dietary
patterns that are very low and high in carbohydrate.
Although the diets were consumed under free-living con-
ditions and nutrient intakes analyzed using food records,
considerable effort was taken to ensure that this was
achieved by the provision of key foods and providing very
prescriptive diet information and menu plans. We noted
that percentage weight loss was greater on the VLCARB
diet compared to the VLF diet, providing possible evi-
dence of a metabolic advantage. We have shown that the
amount of weight loss on a VLCARB diet is greater than
similarly energy restricted higher carbohydrate patterns as
has been observed some decades ago in albeit lower kilo-
joule but isocaloric comparisons [18,20]. Our observation
that this difference was due primarily to loss of lean mass
is consistent with the findings of Vasquez & Adibi [19] but
no isocaloric dietary studies such as ours have been con-
ducted to confirm these findings. As previously shown,
the amount of fat loss was similar on all diets when the
same energy restriction is applied. It is surprising that
despite a higher kilojoule intake than prior studies with a
consequently smaller energy restriction as well as a longer
study duration, we still noted a greater effect on lean mass
loss for the VLCARB pattern. Other authors have argued
Weight loss according to dietary treatment1 Figure 4
Weight loss according to dietary treatment1. 1mean ± 
SEM. VLCARB = very low carbohydrate diet (n = 24) VLF = 
very low fat diet (n = 22) HUF = high unsaturated fat (n = 
21). There were no significant differences in absolute weight 
loss according to dietary treatment.
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that, by reducing plasma insulin levels, a low-carbohy-
drate, ketogenic diet would spare body protein by mini-
mizing the need for gluconeogenesis [21]. Although we
and others [22] did indeed observe greater reductions in
both fasting and post prandial insulin responses on
VLCARB, this was not associated with protein sparing.
Volek et al [23] observed an increase in lean mass in a
small study in normal weight men on a VLCARB in energy
balance but a subsequent study by the same author in
overweight subjects using VLCARB in energy restriction
showed no greater lean mass preservation [24].
One of the key findings of this study was that fasting and
post prandial insulin was lower on the VLCARB diet than
the other two high carbohydrate diets. We believe that the
provision of a glucose tolerance test as well as a "meal
test" was a major strength of this study. The virtual flat line
glucose and insulin response to a low-carbohydrate meal
in the VLCARB group (Figure 5) is remarkable data that
clearly shows how effective this dietary pattern is at stabi-
lizing the metabolic and hormonal milieu that is the goal
for people with insulin resistance and type II diabetes. The
fact that the low-carbohydrate diet did not worsen, and
even improved, the glucose and insulin response to 75 g
Plasma glucose and insulin response for 3 h meal tolerance test (MTT) by dietary treatment1 Figure 5
Plasma glucose and insulin response for 3 h meal tolerance test (MTT) by dietary treatment1. 1Mean (± SEM) 
plasma glucose and insulin concentrations at baseline and 30, 60, 120 and 180 minutes and total AUC after the ingestion of the 
test meals (Table 2B) at weeks 0 and 12. The main effect of the test meals at week 0 and 12 were compared by repeated-meas-
ures ANOVA with week and blood sampling time as within subject factors, and diet as between subject factors. The main 
effect of time (weight loss) for each diet was compared using repeated-measures ANOVA with AUC at week 1 and 12 as 
within subject factors. VLCARB = very low carbohydrate diet (n = 24) VLF = very low fat diet (n = 22) HUF = high unsaturated 
fat (n = 21). * VLCARB test meal significantly different from VLF and HUF test meals at week 0 and week 12, P < 0.01. a 
denotes no significant effect of weight loss within diet group b = significant effect of weight loss within diet group (P < 0.05)
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of glucose further emphasizes the fact that carbohydrate-
restricted diets improve insulin sensitivity provided they
achieve weight loss. Dysregulation of insulin function and
glucose metabolism is the hallmark of diabetes and the
fact that a low-carbohydrate diet can significantly improve
this aspect of metabolism is noteworthy.
Our study is unique in that, unlike previous studies using
whole foods that have used an ad libitum approach in
implementing the dietary strategy, we have attempted to
control and match total kilojoule intake on all diets as
well as introducing an energy balance period to separate
the effects of diet composition and weight loss from
energy restriction. Consequently we observed an increase
in LDL cholesterol on VLCARB compared to a reduction
on the two low saturated fat dietary patterns. This is in
contrast to several previous studies [7,13] who saw no
increase in LDL cholesterol from baseline levels on
VLCARB. This is most likely due to the lowering effect of
weight loss on LDL cholesterol attenuating the expected
rise from an increase in saturated fat intake. This effect of
weight loss on LDL cholesterol has been estimated to be a
reduction of 0.02 mmol/L per kilogram weight loss [25]
whereas the increase in LDL cholesterol for every 1%
Plasma glucose and insulin response (mean ± SEM) for 3 h 75 g oral glucose tolerance test (GTT) by dietary treatment1 Figure 6
Plasma glucose and insulin response (mean ± SEM) for 3 h 75 g oral glucose tolerance test (GTT) by dietary 
treatment1. 1Mean (± SEM) plasma glucose and insulin concentrations at baseline and 30, 60, 120 and 180 minutes and total 
AUC after the ingestion of the 75 g oral glucose drink at weeks 0 and 12. The main effect of diet was compared using repeated-
measures ANOVA with week and blood sampling time as within subject factors, and diet as between subject factors. The main 
effect of time (weight loss) for each diet was compared using repeated-measures ANOVA with AUC at week 1 and 12 as 
within subject factors. * VLCARB significantly different overall from VLF and HUF at week 0 and week 12, P < 0.01. a = no sig-
nificant effect of weight loss within diet group. b = significant effect of weight loss within diet group (P < 0.05). VLCARB = very 
low carbohydrate diet (n = 24) VLF = very low fat diet (n = 22) HUF = high unsaturated fat (n = 21).
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energy increase in saturated fatty acids is estimated to be
0.03 mmol/L [26]. Therefore the likely net effect on LDL
cholesterol with weight loss on VLCARB will be a balance
between how much weight is lost versus the increase in
saturated fatty acids. For small weight losses the impact is
likely to represent a net increase in LDL cholesterol
whereas for moderate weight losses this effect may be neu-
tral. However, the cardiovascular risk represented by these
changes in LDL cholesterol are not clear as Sharman
showed that more men with "pattern B" had switched to
"pattern A" after 6 wk of intake of a very low-carbohydrate
diet (75%) compared with a low-fat diet (42%) [27]. An
examination of the effect on apoB concentrations revealed
no significant effect of diet composition on repeated
measures ANOVA although both VLF and HUF resulted in
a net lowering of apoB concentrations (P < 0.05 Students
paired t test) whereas for VLCARB it remained unchanged
from baseline despite a significant fall during active
weight loss. This represents a balance between the rise in
cholesterol-rich particles and the fall in triacylglycerol-
rich particles with this diet. Volek et al have proposed a
model of lipoprotein metabolism on VLCARB diets that is
consistent with the observed decrease in triacylglycerols
concentrations, increase in HDL-Cholesterol, and a redis-
tribution of LDL to a larger particle size [28]. We did
observe a significant effect of gender to the apoB response
to refeeding to weight maintenance (P < 0.05). This has
not previously been described and suggests that in men,
apoB may be more resistant to caloric flux than in women.
ApoB may arguably be a better predictor of vascular risk
[29] although there is some controversy in this area.
When triacylglycerol is elevated, such as in people with
type 2 diabetics, apoB (or non HDL cholesterol) is clearly
superior but this may not be true in people with normal
triacylglycerol levels. We also observed a diet effect on
apoB48 which was unexpected and may be related to high
fat diets increasing chylomicron clearance.
The greater triacylglycerol reduction on VLCARB is in
keeping with what is anticipated on isocaloric lower car-
bohydrate patterns and also consistent with what has
been observed in longer term ad libitum studies when
adjusted for weight loss [11,13,26,30]. Low HDL-C and
hypertriglyceridemia have been shown to be independ-
ently related to the risk of myocardial infarction (31–33).
In the Veterans Affairs High – Density Lipoprotein Inter-
vention Trial [33] which used gemfibrozil, it was observed
that for every 1% increase in HDL-C, there was a 3%
reduction in death or myocardial infarction although not
all of this effect was attributed to the effect on HDL-C. It
is therefore, possible that weight loss on dietary patterns
that are very low in carbohydrate and which improve
these risk factors may be therapeutic for subjects with this
pattern of dyslipidaemia despite much of the fat being sat-
urated. However there is currently minimal evidence that
increasing HDL cholesterol with fat is protective.
CRP is an independent risk factor for cardiovascular dis-
ease and abdominal obesity is associated with elevations
of CRP [34]. In the present study weight loss per se
resulted in a reduction in CRP irrespective of dietary
macronutrient composition. Reduction in CRP with
weight loss has been observed previously by us in a study
using very-low-fat diets and in a recent study when CRP
fell irrespective of dietary macronutrient composition
[35,36]. Others al have also reported reductions in CRP
on VLCARB [37,38]. We also observed a beneficial effect
on blood pressure with weight loss which was independ-
ent of diet composition. Other authors have reported
blood pressure reductions with modest weight loss [39].
There is known to be a strong positive association
between systolic blood pressure and increasing risk of
stroke and cardiovascular disease, and reductions in systo-
lic blood pressure contributes to overall CVD risk reduc-
tion [40].
Table 6: 24 hour urinary excretion of Calcium, Sodium, Potassium and Crosslinks before and after weight loss1
VLCARB VLF HUF
Baseline 12 weeks Baseline 12 Weeks Baseline 12 Weeks
Calcium2 mmol/24 hr 4.9 ± 0.5 6.1 ± 0.6a 4.3 ± 0.4 3.6 ± 0.4b,c 4.3 ± 0.6 3.8 ± 0.5a,c
Sodium3 mmol/24 hr 172.7 ± 16.2 163.6 ± 15.2 173.9 ± 10.6 168.3 ± 13.1 175.4 ± 16.5 141.6 ± 11.9
Potassium4 mmol/24 hr 80.0 ± 4.8 65.2 ± 3.9a 83.2 ± 5.7 98.1 ± 5.8b,c 77.8 ± 5.9 74.3 ± 5.0a,c
Deoxypyridinoline:creatinine5 nmol/mmol 18.0 ± 1.0 20.5 ± 1.6 21.2 ± 1.5 23.1 ± 1.5 19.4 ± 1.1 22.4 ± 1.2
Pyridinoline:creatinine5 nmol/mmol 64.5 ± 3.0 73.3 ± 4.2 71.9 ± 5.3 83.9 ± 5.7 67.0 ± 2.9 77.1 ± 3.0
1 Mean ± SEM
2 Main effect of diet p = 0.025 using repeated measures ANOVA. Variables with different superscripts are significantly different using Tukey's test 
for post hoc analysis (P < 0.05).
3 No significant effect of time or diet using repeated measures ANOVA
4 Main effect of diet P < 0.001. Variables with different superscripts are significantly different using Tukey's test for post hoc analysis (P < 0.05).
5 Main effect of time using repeated measures ANOVA P < 0.0001
VLCARB = very low carbohydrate diet (n = 24) VLF = very low fat diet (n = 22) HUF = high unsaturated fat (n = 21)Nutrition & Metabolism 2006, 3:7 http://www.nutritionandmetabolism.com/content/3/1/7
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The very low insulin response observed following the
VLCARB test meal was unexpected given that protein is
well known to stimulate insulin secretion[41]. However it
is likely that the large amount of fat in the test meal mark-
edly delayed gastric emptying of the protein and blunted
the rise in insulin [42]. Although apparent glucose toler-
ance did not change with weight loss on VLCARB, the
insulin response to both glucose and the test meals was
lowered suggesting improvements in insulin sensitivity.
The other cardiovascular risk factor which worsened on
VLCARB was plasma homocysteine which increased by
6.6% despite no differences in plasma folate. This small
increase in homocysteine may or may not have clinical
significance as homocysteine levels after the VLCARB diet
were low at 7.76 umol/L, which are below values that are
indicative of higher risk for cardiovascular disease. Hyper-
homocysteinemia was found to be an independent risk
factor for cardiovascular disease in a prospective study of
plasma homocysteine and risk of myocardial infarction in
US physicians [43] although in men free of coronary dis-
ease high circulating homocysteine concentrations were
not a risk factor for acute coronary events. The same study
showed that folate concentrations are inversely associated
with the incidence of acute coronary events. In our study,
folate concentrations were measured during energy bal-
ance during which time absolute carbohydrate intake and
vegetable intake were higher than during the energy
restriction period. Hence it is possible that plasma folate
levels were lower during the energy restriction period sug-
gesting a need for folate supplementation on VLCARB die-
tary patterns. Although mandatory folate fortification
does not occur in Australia, it is likely that such fortifica-
tion which does occur in countries such as the US may
minimize these effects.
We noted an increase in calcium excretion on VLCARB.
This is in contrast to a reported previous report from our
group which showed that while weight loss was associated
with increased bone resorption on a higher protein diet
(34% energy from protein) calcium excretion decreased
[44]. Metabolism of dietary protein (particularly fish,
meat, and cheese) is associated with acid generation,
which can reduce blood pH and cause obligatory calcium
losses whereas metabolism of fruit, and vegetables (both
of which were low in VLCARB) produces alkali, which can
partially ameliorate the effect of this acid [45,46]. On the
other hand, a protein intake greater than 87 g/day is
related to improved lower limb bone mass in elderly
women. Calcium intake on VLCARB was significantly
higher than on VLF and not different to HUF. Hence the
possible adverse effects of long term use of VLCARB die-
tary patterns on bone mass remains speculative.
Conclusion
Under isocaloric conditions VLCARB results in similar fat
loss to other conventional dietary patterns although the
greater percent weight loss is suggestive of a metabolic
advantage. VLCARB resulted in equal improvements in
most cardiovascular risk factors compared to conven-
tional weight loss diets while the triacylglycerol reduction
offset the LDL cholesterol rise. The more favorable effects
of VLCARB on fasting and post prandial plasma insulin
concentrations is a significant observation which indi-
cates that this dietary pattern may be a useful strategy for
the short-term management of subjects with insulin resist-
ance and hypertriacylglycerolemia.
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